Helix BioPharma names Markus Loeffler chief medical officer

Reuters2026/08/17 21:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Helix BioPharma appointed Markus Loeffler as chief medical officer as it shifts into a more execution-focused phase of clinical development.
Loeffler will lead clinical strategy, including a planned Phase Ib/II study of L-DOS47 with pembrolizumab in first-line NSCLC.
He will also guide LEUMUNA toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Loeffler is a physician-scientist with more than 30 years in oncology drug development, including senior roles at Roche.
He previously led the Phase III program for Lutathera, later approved for certain gastroenteropancreatic neuroendocrine tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helix BioPharma Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608171715TNWSWRCACNPR_____1ArbFWK1P) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Helix BioPharma names Markus Loeffler chief medical officer

You may also like

Crypto prices